Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. (Nasdaq: ZVRA) is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. Its marketed products include MIPLYFFA (arimoclomol), approved in the United States for neurological manifestations of Niemann-Pick disease type C in adults… From the company’s description.
Over the twelve months to Sep 30, 2026, Zevra Therapeutics, Inc. reported revenue of $147.76M, up 75.1% from a year earlier, and net income of $78.02M. Its operating margin was 60.8%, and operations generated $38.74M in cash. In fiscal 2025, it reported revenue of $106.47M, up 350.9% from fiscal 2024, and net income of $83.23M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Zevra Therapeutics, Inc. does
In the company’s own words
Zevra Therapeutics, Inc. (Nasdaq: ZVRA) is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases. Its marketed products include MIPLYFFA (arimoclomol), approved in the United States for neurological manifestations of Niemann-Pick disease type C in adults and children aged two and older, and OLPRUVA (sodium phenylbutyrate), approved for certain urea cycle disorders. Zevra is pursuing European approval for MIPLYFFA and is evaluating strategic alternatives for OLPRUVA. Its pipeline includes celiprolol, in a Phase 3 trial for vascular Ehlers-Danlos syndrome, and KP1077, a serdexmethylphenidate candidate being developed for idiopathic hypersomnia and narcolepsy. The company also receives royalties and potential milestone payments from AZSTARYS, an ADHD treatment licensed to Commave for development, manufacture and commercialization. Zevra acquired arimoclomol-related assets from Orphazyme in 2022 and acquired Acer Therapeutics, including OLPRUVA and celiprolol, in 2023. The company reported $0.8 million in OLPRUVA sales revenue for 2025. Its website is www.zevra.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1434647
- SIC
- 2834
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Zevra Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Zevra Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Zevra Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Zevra Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Zevra Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”